Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.07 USD | +2.01% | -6.44% | +175.00% |
Sales 2024 * | 242K 20.22M | Sales 2025 * | 66.67K 5.56M | Capitalization | 182M 15.16B |
---|---|---|---|---|---|
Net income 2024 * | -46M -3.84B | Net income 2025 * | -57M -4.75B | EV / Sales 2024 * | 750 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2,727 x |
P/E ratio 2024 * |
-4.17
x | P/E ratio 2025 * |
-3.86
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.32% |
Latest transcript on Cardiff Oncology, Inc.
1 day | +2.01% | ||
1 week | -6.44% | ||
Current month | -23.78% | ||
1 month | -24.49% | ||
3 months | +173.15% | ||
6 months | +295.15% | ||
Current year | +175.00% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 04/13/04 |
James Levine
DFI | Director of Finance/CFO | 53 | 12/21/12 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 11/22/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 22/20/22 |
Gary Pace
BRD | Director/Board Member | 76 | 22/20/22 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 04/13/04 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 4.07 | +2.01% | 516,215 |
25/24/25 | 3.99 | -4.55% | 586,641 |
24/24/24 | 4.18 | +0.24% | 343,293 |
23/24/23 | 4.17 | -4.36% | 702,313 |
22/24/22 | 4.36 | +0.23% | 462,511 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+175.00% | 182M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CRDF Stock